Beam Therapeutics (BEAM) EBIT Margin (2019 - 2025)
Historic EBIT Margin for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to 1307.6%.
- Beam Therapeutics' EBIT Margin fell 5612000.0% to 1307.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 837.12%, marking a year-over-year decrease of 7848800.0%. This contributed to the annual value of 654.25% for FY2024, which is 6075300.0% down from last year.
- According to the latest figures from Q3 2025, Beam Therapeutics' EBIT Margin is 1307.6%, which was down 5612000.0% from 1419.22% recorded in Q2 2025.
- Beam Therapeutics' 5-year EBIT Margin high stood at 42.02% for Q4 2023, and its period low was 3339550.0% during Q1 2021.
- Its 5-year average for EBIT Margin is 228595.9%, with a median of 746.4% in 2024.
- In the last 5 years, Beam Therapeutics' EBIT Margin tumbled by 2000000000bps in 2021 and then skyrocketed by 2000000000bps in 2022.
- Quarter analysis of 5 years shows Beam Therapeutics' EBIT Margin stood at 124.31% in 2021, then crashed by -257bps to 444.1% in 2022, then skyrocketed by 109bps to 42.02% in 2023, then plummeted by -892bps to 332.71% in 2024, then plummeted by -293bps to 1307.6% in 2025.
- Its EBIT Margin stands at 1307.6% for Q3 2025, versus 1419.22% for Q2 2025 and 1596.87% for Q1 2025.